Correction: Brivanib attenuates hepatic fibrosis in vivo and stellate cell activation in vitro by inhibition of FGF, VEGF and PDGF signaling

Ikuo Nakamura, Kais Zakharia, Bubu A. Banini, Dalia S. Mikhail, Tae Hyo Kim, Ju Dong Yang, Catherine D. Moser, Hassan M. Shaleh, Sarah R. Thornburgh, Ian Walters, Lewis Rowland Roberts

Research output: Contribution to journalArticle

1 Scopus citations
Original languageEnglish (US)
Article numbere0142355
JournalPLoS One
Volume10
Issue number11
DOIs
StatePublished - Nov 3 2015

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Nakamura, I., Zakharia, K., Banini, B. A., Mikhail, D. S., Kim, T. H., Yang, J. D., Moser, C. D., Shaleh, H. M., Thornburgh, S. R., Walters, I., & Roberts, L. R. (2015). Correction: Brivanib attenuates hepatic fibrosis in vivo and stellate cell activation in vitro by inhibition of FGF, VEGF and PDGF signaling. PLoS One, 10(11), [e0142355]. https://doi.org/10.1371/journal.pone.0142355